Nanobac Pharmaceuticals, Incorporated
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NNBP research report →
Price Chart
About the company
Nanobac Pharmaceuticals, Incorporated is dedicated to advancing human health through the creation and refinement of products and services designed for the identification and management of calcifying nanoparticles (CNPs). The company's offerings include the production and sale of in vitro diagnostic (IVD) kits, which encompass assays, antibodies, and reagents specifically developed for detecting CNPs. Notably, their diagnostic assays include NANO-CAPTURE and NANO-SERO.
- CEO
- John Stanton
- IPO
- 1994
- Employees
- 1
- HQ
- Tampa, FL, US
Get TickerSpark's AI analysis on NNBP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $24.95K
- P/E
- 0.00
- PEG
- 0.00
- P/S
- 1.42
- P/B
- 0.00
- EV/EBITDA
- -0.70
- Div Yield
- 0.00%
- Gross Margin
- 17.60%
- Op Margin
- 27891.78%
- Net Margin
- -37319.74%
- ROE
- 357.99%
- ROIC
- 106.93%
Latest fiscal year · YoY change
- Revenue
- $17.62K-92.2%
- Gross Profit
- $3.10K-97.9%
- Op Income
- $4.91M
- Net Income
- $-6,576,111-32.2%
- EPS
- $0.00+100.0%
- OCF Growth
- +64.8%
- FCF Growth
- +64.9%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -8.83
- RSI (14)
- 52
- Avg Volume
- 129
No earnings-call transcripts are available for NNBP yet.
- Free Float
- 39.2%
- Shares Outstanding
- 249.51M
- Float Shares
- 97.77M
Our NNBP coverage
Recent articles, reports, and earnings notes.
No research on NNBP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NNBP report →